Anew Medical Receives European Patent for Klotho as Treatment for Neurodegenerative Diseases
Anew Medical (WENA) said Wednesday that it received a patent in Europe for the use of its Klotho gene sequence and gene delivery systems for the treatment of diminished cognition, memory loss, dementia, and other neurodegenerative diseases.
The company said the product's key intellectual property asset is covered under its exclusive worldwide license deal with Universitat Autonoma de Barcelona and Institucio Catalana de Recerca i Estudis Avancats in Spain.
Anew Medical it has also patent approval in China and Hong Kong, and that it plans to start product development and further expand its intellectual property portfolios into Asian markets this year.
Price: 1.6200, Change: -0.03, Percent Change: -1.82
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。